Literature DB >> 25216372

Stem cells for cell replacement therapy: a therapeutic strategy for HD?

Anne Rosser1, Clive N Svendsen.   

Abstract

Much interest has been expressed over the last couple of decades in the potential application of stem cells to medicine, both for research and diagnostic tools and as a source of donor cells for therapeutic purposes. Potential therapeutic applications include replacement of cells in many body organs where the capacity for intrinsic repair is limited, including the pancreas, heart, and brain. A key challenge is to generate the relevant donor cell types, and this is particularly challenging in the brain where the number of different neuronal subtypes is so great. Although dopamine neuron replacement in Parkinson's disease has been the focus of most clinical studies, great interest has been shown in this approach for other disorders, including Huntington's disease. Replacing complete neural circuits in the adult brain is clearly challenging, and there are many other complexities with regard to both donor cells and host. This article presents the pros and cons of taking a cell therapy approach in Huntington's disease. It considers the implantation both of cells that are already of the same neural subtype as those lost in the disease process (ie, primary fetal cells derived from the developing striatum) and those derived from stem cells, which require "directing" toward that phenotype.
© 2014 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Huntington's; cell therapy; fetal cells; graft; neural transplant; stem cells

Mesh:

Year:  2014        PMID: 25216372     DOI: 10.1002/mds.26026

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  9 in total

Review 1.  The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomes.

Authors:  Javier Fernández-Ruiz
Journal:  Br J Pharmacol       Date:  2018-07-08       Impact factor: 8.739

Review 2.  Induced Pluripotent Stem Cells in Huntington's Disease: Disease Modeling and the Potential for Cell-Based Therapy.

Authors:  Ling Liu; Jin-Sha Huang; Chao Han; Guo-Xin Zhang; Xiao-Yun Xu; Yan Shen; Jie Li; Hai-Yang Jiang; Zhi-Cheng Lin; Nian Xiong; Tao Wang
Journal:  Mol Neurobiol       Date:  2015-12-10       Impact factor: 5.590

3.  Technological Approach to Mind Everywhere: An Experimentally-Grounded Framework for Understanding Diverse Bodies and Minds.

Authors:  Michael Levin
Journal:  Front Syst Neurosci       Date:  2022-03-24

Review 4.  Neurotrophic Factors and Their Potential Applications in Tissue Regeneration.

Authors:  Nan Xiao; Quynh-Thu Le
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2015-11-26       Impact factor: 4.291

5.  Nicotinamide alone accelerates the conversion of mouse embryonic stem cells into mature neuronal populations.

Authors:  Síle M Griffin; Mark R Pickard; Rowan P Orme; Clive P Hawkins; Adrian C Williams; Rosemary A Fricker
Journal:  PLoS One       Date:  2017-08-17       Impact factor: 3.240

6.  Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration.

Authors:  José Aguareles; Juan Paraíso-Luna; Belén Palomares; Raquel Bajo-Grañeras; Carmen Navarrete; Andrea Ruiz-Calvo; Daniel García-Rincón; Elena García-Taboada; Manuel Guzmán; Eduardo Muñoz; Ismael Galve-Roperh
Journal:  Transl Neurodegener       Date:  2019-03-08       Impact factor: 8.014

7.  Protocol for an open label: phase I trial within a cohort of foetal cell transplants in people with Huntington's disease.

Authors:  Cheney J G Drew; Feras Sharouf; Elizabeth Randell; Lucy Brookes-Howell; Kim Smallman; Bernadette Sewell; Astrid Burrell; Nigel Kirby; Laura Mills; Sophie Precious; Philip Pallmann; David Gillespie; Kerry Hood; Monica Busse; William P Gray; Anne Rosser
Journal:  Brain Commun       Date:  2021-01-19

8.  Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: a phase I clinical trial.

Authors:  Hee Jin Kim; Kyung Rae Cho; Hyemin Jang; Na Kyung Lee; Young Hee Jung; Jun Pyo Kim; Jung Il Lee; Jong Wook Chang; Seongbeom Park; Sung Tae Kim; Seung Whan Moon; Sang Won Seo; Soo Jin Choi; Duk L Na
Journal:  Alzheimers Res Ther       Date:  2021-09-14       Impact factor: 6.982

9.  Transplantation of human embryonic stem cells alleviates motor dysfunction in AAV2-Htt171-82Q transfected rat model of Huntington's disease.

Authors:  Jaisan Islam; Kyoung Ha So; Elina Kc; Hyeong Cheol Moon; Aryun Kim; Sang Hwan Hyun; Soochong Kim; Young Seok Park
Journal:  Stem Cell Res Ther       Date:  2021-11-22       Impact factor: 6.832

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.